RxDoctor Payments Data

David Ruckman, MD

Internal Medicine · Fullerton, CANPI 1285620658

Payments from drug & device makers

$1,033in general payments, 2019–2025

Across 53 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$330
  • Amgen$228
  • E.r. Squibb & Sons, L.L.C.$116
  • Johnson & Johnson$80
  • AbbVie$76
  • GSK$73
  • plus $130 from 5 others

What the payments were for

  • Consulting fees$202%
  • Food & beverage$85783%
  • Education$15715%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,033 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$180,439
Medicare patients
375
Services billed
6,108

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban191$182,231
JardianceEmpagliflozin101$123,554
JanuviaSitagliptin Phosphate82$69,998
MyrbetriqMirabegron44$35,126
TrulicityDulaglutide16$33,614
XareltoRivaroxaban17$30,234
OzempicSemaglutide22$26,367
Breo ElliptaFluticasone/Vilanterol24$17,834
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$16,230
OxycontinOxycodone Hcl21$9,374
Atorvastatin Calcium798$9,124
LinzessLinaclotide12$7,628
PremarinEstrogens, Conjugated13$7,521
Levothyroxine Sodium503$6,811
Pantoprazole Sodium319$5,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$58$189,752204 claims
Astellas Pharma US IncMyrbetriq$330$35,12644 claims
GSKBreo Ellipta, Trelegy Ellipta$73$34,06437 claims
Lilly USA, LLCTrulicity$23$33,61416 claims
Johnson & JohnsonXarelto$80$30,23417 claims
AbbVieLinzess, Synthroid$76$13,43791 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →